NCT06876363 - Study of EN-374 Gene Therapy in Participants With X-Linked Chronic Granulomatous Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 5, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

X-Linked Chronic Granulomatous Disease

Interventions

GENETIC

EN-374

Single dose of EN-374 administered by intravenous infusion after mobilization and followed by enrichment

Trial Locations (3)

RECRUITING

Columbia University Irving Medical Center, Morgan Stanley Children's Hospital, New York

RECRUITING

University of Minnesota, Minneapolis

RECRUITING

University of Utah, Primary Children's Hospital, Salt Lake City